大补阴丸对链脲佐菌素诱导大鼠糖尿病模型的影响

目的 研究大补阴丸对链脲佐菌素大鼠糖尿病模型的治疗作用.方法 将85只SPF级SD大鼠采用随机数字表法分为空白对照组、模型对照组、大补阴丸低剂量组(1.62 g/kg)、大补阴丸中剂量组(3.24 g/kg)、大补阴丸高剂量组(6.48 g/kg)、二甲双胍对照组(300 mg/kg).除空白对照组外其余大鼠腹腔注射浓度为11 mg/mL的链脲佐菌素(Streptozotocin,STZ,5 mL/kg).连续灌胃给药治疗12周.末次给药前一天测随机血糖,末次给药1 h后测空腹血糖及血糖曲线下面积,实验结束时大鼠用10％水合氯醛麻醉,腹主动脉取血,用于血脂的检测,最后取肾脏和肝脏福尔马林固定,用于HE染色.结果 与空白对照组相比[治疗前(87.5±6.3)mg/dL和治疗后(79.2±5.0)mg/dL],模型对照组的初始随机血糖[(419.5±63.8)mg/dL]、治疗后的随机血糖[(387.2±67.5)mg/dL]均显著高于对照组(t=12.768、12.273,P<0.05).与模型对照组相比,各治疗组初始随机血糖差异无统计学意义(P>0.05).与模型对照组相比,大补阴丸高剂量组[(309±62.4)mg/dL]、二甲双胍对照组[(285±53.7)mg/dL]治疗后的随机血糖均显著降低(t=4.072、3.116,P<0.05).大补阴丸中剂量组、高剂量组、二甲双胍对照组治疗后的随机血糖下降率大于20％.与模型对照组[(2.32±0.38)mmol/L、(0.91±0.11)mmol/L]相比,大补阴丸中剂量组[(1.91±0.28)mmol/L、(0.78±0.07)mmol/L]、高剂量组[(1.72±0.31)mmol/L、(0.72±0.09)mmol/L]和二甲双胍对照组[(1.65±0.25)mmol/L、(0.71±0.06)mmol/L]的血清总胆固醇、总三酰甘油水平均显著降低(t=2.965、4.339、4.845,t=3.020、4.413、4.646,P<0.05).与模型对照组相比[(0.75±0.07)mmol/L],大补阴丸低剂量组[(0.67±0.05)mmol/L]、中剂量组[(0.61±0.07)mmol/L]、高剂量组[(0.58±0.06)mmol/L]和二甲双胍对照组[(0.57±0.08)mmol/L]的血清低密度脂蛋白均显著降低(t=2.723、4.765、5.786、6.126,P<0.05).与模型对照组[(0.42±0.08)mmol/L]相比,大补阴丸中剂量组[(0.51±0.07)mmol/L]、高剂量组[(0.50±0.05)mmol/L]和二甲双胍对照组[(0.49±0.06)mmol/L]的高密度脂蛋白均显著增加(t=2.946、2.619、2.291,P<0.05).结论 大补阴丸具有降低糖尿病模型大鼠血糖和血脂的作用,并且能减轻糖尿病模型大鼠的肝肾损害.

Effect of Dabuyin pill on streptozotocin-induced diabetes in rats

Objective To study the therapeutic effect of Dabuyin pill on diabetic model of streptozotocin in rats.Methods Eighty-five SPF SD rats were divided into blank control group, model control group, low-dose group of Dabuyin pill (1.62 g/kg), middle-dose group of Dabuyin pill (3.24 g/kg), high-dose group of Dabuyin pill (6.48 g/kg) and metformin group (300 mg/kg). Except the blank control group, the rats were intraperitoneally injected with STZ (5 mL/kg) at a concentration of 11 mg/mL. Continuous intragastric administration for 12 weeks. Random blood glucose was measured one day before the last administration. The area under the curve of fastingblood glucose and blood glucose time was measured 1 hour after the last administration. At the end of the experiment, the rats wereanesthetized with 10% chloral hydrate, and the abdominal aorta was taken for blood lipid detection. Finally, kidney and liver formalinwere fixed for HE staining.Results Compared with the blank control group [before treatment (87.5 ± 6.3) mg/dL and after treatment(79.2 ± 5.0) mg/dL], the initial random blood glucose [(419.5 ± 63.8) mg/dL] and post-treatment random blood glucose [(387.2 ± 67.5)mg / dl] in the model control group were significantly higher than those in the control group (t=12.768, 12.273, P<0.05). Compared withthe model control group, there was no statistically significant difference in the initial random blood glucose of each treatment group (P> 0.05). Compared with the model control group, the high-dose group of Dabuyin pill [(309±62.4) mg/dL] and the metformin control group [(285±53.7) mg/dL] had significantly lower random blood glucose after treatment (t=4.072,3.116,P<0.05). The random blood glucose reduction rate after treatment in the middle-dose group of Dabuyin pill, the high-dose group and the metformin control group was greaterthan 20%. Compared with the model control group [(2.32±0.38)mmol/L, (0.91±0.11) mmol/L], the serum total cholesterol and total triglyceride levels of the middle-dose group of Dabuyin pill [(1.91 ± 0.28) mmol/L, (0.78 ± 0.07) mmol/L], the high-dose group [(1.72±0.31) mmol/L, (0.72±0.09) mmol/L] and the metformin control group [(1.65±0.25) mmol/L, (0.71±0.06) mmol/L] were decreased significantly (t=2.965, 4.339 , 4.845, t=3.020, 4.413, 4.646, P<0.05). Compared with the model control group [(0.75±0.07) mmol/L], the serum low-density lipoproteins level of the low-dose group of Dabuyin pill [(0.67±0.05) mmol/L], the middle-dose group [(0.61±0.07) mmol/L], the high-dose group [(0.58±0.06) mmol/L] and the metformin control group [(0.57±0.08) mmol/L] were all decreased significantly (t=2.723, 4.765, 5.786, 6.126, P<0.05). Compared with the model control group [(0.42±0.08) mmol/L], the high density lipoprotein level of the middle-dose group of Dabuyin pill [(0.51±0.07) mmol/L], the high-dose group [(0.50±0.05) mmol/L] and the metformin control group [(0.49±0.06) mmol/L] were all increased significantly (t=2.723, 4.765, 5.786, 6.126, P<0.05).Conclusion Dabuyin pillhas the effect of reducing blood sugar and blood lipid in diabetic model rats, and can alleviate liver and kidney damage in diabetic model rats.